SP1-JTI

The complexity of the balance of plant of a fuel cell-fuel processor unit challenges the design/development/demonstration of compact and user friendly fuel cell power systems for portable applications. An Internal Reforming Methanol Fuel Cell (IRMFC) stack poses a highly potential technological challenge for High Temperature Polymer Electrolyte Membrane Fuel Cells (HT-PEMFCs) in portable applications. It aims at opening new scientific and engineering prospects, which may allow easier market penetration of the fuel cells.

The SESAMO project addresses the root causes of problems arising with convergence of safety and security in embedded systems at architectural level, where subtle and poorly understood interactions between functional safety and security mechanisms impede system definition, development, certification, and accreditation procedures and standards. Intense market innovation is being held back by this root cause: the absence of a rigorous theoretical and practical understanding of safety and security feature interaction.

Novel low temperature fuel cell (FC) cathode catalyst and support systems will be designed and synthesized. The focus will be on highly active catalyst materials for polymer electrolyte membrane fuel cells (PEMFC) for transportation applications.

European Autism Interventions - A Multicentre Study for Developing New Medications (EU-AIMS) - is the largest single grant for autism in the world, and the largest for the study of any mental health disorder in Europe.

EUPATI stands for 'European Patients Academy on Therapeutic Innovation'. This innovative patient-led academy will lead an ambitious project to develop educational material, training courses and a public Internet library to educate patient representatives and the lay public about all processes involved in medicines development. It will address topics like personalised and predictive medicine, design and conduct of clinical trials, drug safety and risk/benefit assessment, health economics as well as patient involvement in drug development.

GetReal is a project of the Innovative Medicines Initiative (IMI), a public-private consortium consisting of pharmaceutical companies, academia, HTA agencies and regulators (e.g., NICE, HAS, EMA and ZIN), patient organisations and SMEs.

Drug Induced Liver Injury (DILI) is a major health problem with broad implications for patients, health care professionals, the pharmaceutical industry and drug regulatory agencies. The current test systems employed by the pharmaceutical industry are poorly predictive for DILI. The Mechanism Based Integrated Systems for the Prediction of Drug Induced Liver Injury (MIP-DILI) project will address this situation by the development of innovative preclinical test systems. These will be both mechanism-based and of physiological, pharmacological and pathological relevance to DILI in humans.

The ORBIT Project is a research project co-funded by the European Commission in the Seventh Framework Programme (FP7) under the Objective ICT-2013.1.6 Connected and Social Media (project number 611312). The Seventh Framework Programme for research and technological development (FP7) is the European Union’s main instrument for funding research over the period 2007 to 2013.

PREDECT is one of the major Innovative Medicines Initiatives (IMI) of the European Union with 21 laboratories collaborating in a Public-Private partnership, aiming to create more appropriate in vitro platforms for target validation and drug discovery. Partners include pharmaceutical industry, academic and biotech laboratories. Genomic and proteomic data on cancers from patient material provides hypotheses regarding potential novel drug targets.

Excellent care for people with suspected infections involves rapid diagnosis and treatment. For instance, administering the correct antibiotic as soon as possible to patients with blood infections, dramatically improves their chances of survival. Equally so, using antibiotics when they do not benefit patients exposes them unnecessarily to side effects and potential antibiotic resistance. In this modern age, we still do not have the technology available that can quickly diagnose what kind of infection and what treatment is needed.